OrganaBio Acquires Excellos Assets to Create Bicoastal Cell Therapy Manufacturing Network
核心洞察
OrganaBio (搜索) LLC has acquired substantially all operating assets of San Diego-based Excellos (搜索) Inc. to establish a comprehensive bicoastal cell therapy contract development and manufacturing organization.
The acquisition creates geographic and infrastructure redundancy for cell therapy developers, addressing supply chain risks while maintaining quality consistency under a single framework.
The combined platform now spans multiple facilities across the US, supporting therapeutic programs concentrated in cancer (搜索) and autoimmune (搜索) indications for top pharmaceutical companies.
OrganaBio (搜索) LLC has acquired substantially all operating assets of San Diego-based Excellos (搜索) Inc., creating a comprehensive bicoastal cell therapy contract development and manufacturing organization that addresses critical supply chain challenges facing the cell therapy industry.
The newly formed OrganaBio (搜索) subsidiary Excellos (搜索) Labs, LLC will oversee San Diego operations, combining complementary capabilities while expanding geographic coverage. The acquisition creates a more comprehensive cell therapy service provider that leverages manufacturing, PBMC isolation, and cryopreservation services across multiple facilities, supporting cell therapy programs from preclinical through commercial supply.
Addressing Industry Supply Chain Challenges
The combined organization is positioned to solve a structural challenge for cell therapy developers requiring PBMC isolation and cryopreservation services. According to the companies, dependency on a single source for these services creates supply chain risks, while splitting volume across multiple vendors introduces quality risks such as lot-to-lot variability and inconsistent process execution across sites.
OrganaBio (搜索) now offers bicoastal cGMP manufacturing, PBMC isolation for clinical trial samples, and cryopreservation of patient leukopaks ahead of manufacturing, all operating under a single quality framework. This approach delivers geographic and infrastructure redundancy without the typical trade-offs, potentially shortening the path from cell therapy development to patients.
Expanded Geographic Footprint
The company's combined platform spans multiple facilities across the United States. OrganaBio (搜索)'s Miami headquarters anchors the East Coast operations with adult leukapheresis through its HemaCenter (搜索) subsidiary, birth tissue and cord blood sourcing via its GaiaGift (搜索) subsidiary, ISO 7 cGMP cleanrooms, process development, QC/analytical testing, PBMC isolation, and cryopreservation.
On the West Coast, OrganaBio (搜索) operates cell processing and cryopreservation labs in San Francisco and Irvine, California, and now adds Excellos (搜索)' downtown San Diego facility. The San Diego site is a purpose-built facility featuring five ISO 7 cGMP cleanroom suites supporting autologous and allogeneic cell therapy manufacturing, cell isolation and enrichment, expansion, and fill/finish operations.
Customer Base and Therapeutic Focus
The combined customer base includes many of the top 20 global pharmaceutical companies along with a broad set of public and private biotechnology developers. Therapeutic programs supported across the platform are concentrated in cancer (搜索) and autoimmune (搜索) indications, spanning autologous and allogeneic cell therapies in clinical and commercial development.
"Cell therapy developers and the patients waiting on their programs need a manufacturing partner that can match the pace and quality of their work," said Justin Irizarry, CEO of OrganaBio (搜索). "Combining OrganaBio's and Excellos (搜索)' infrastructure and teams lets us do that more reliably than either company could alone."
Tom VanCott, CEO of Excellos (搜索), emphasized the strategic benefits: "This acquisition is the best of both worlds, ensuring continuity for Excellos' customers as we move into our next phase while adding critical redundancy, expanded geographical reach, and access to additional services and material including cord blood."
Integration Timeline and Operational Continuity
The core Excellos (搜索) team has been retained to ensure existing customer programs continue without interruption. In the near term, both organizations will maintain existing operations for customers and partners, with OrganaBio (搜索)'s priority being operational continuity for every customer of both companies.
Full integration is expected over the next 12 months, with a focus on operational speed and quality, expanding services, and supporting continued growth across the combined platform. Broader capabilities will be layered in as integration progresses.
Excellos (搜索) was founded in 2021 as an independent spinout of the San Diego Blood Bank (搜索), delivering apheresis donor cell collection, cell processing, cell isolation and enrichment, transduction, expansion, fill/finish, and third-party cryopreservation services under cGMP. OrganaBio (搜索) operates as a vertically integrated cell therapy contract development and manufacturing organization through its FDA-registered subsidiaries, maintaining proprietary supply chains for ethically sourced human tissues and blood-derived cellular products.